

Sr. No.	Product Name*	Regulatory Authority	Date of Submission	Number Assigned as on date
1.	Pyrazinamide	US FDA	31.07.01	15553 dt. 06 November 2001
		EDQM	24.03.00	R1-CEP2000-036 Rev-02 dt. 01 March 2012
		WHO	01.09.08	APIMF 078 Prequalified dt. 01 December 2011
		Canada	18.02.03	DMF-2003-026 dt. 07 March 2003
		Russia	01.11.04	Il no. 15845/01 dt. 03 April 2008
		KFDA	23.04.09	20090924-110-F-42-03 received on dt. 01 October 2009
		Netherlands	29.03.00	DMF No. 0728 dt. 05 December 2000
		Australia	30.10.04	2004/83649 dt.16 December 2004
		Greece	05.09.01	Ref. No. 831 dt. 5 October 2001
		Ukraine	15.07.08	UA/8551/01/01 dt. 24 September 2008
		Newzealand	30.10.04	TT60-882-13-1 dt. 12 November 2004
2.	Zopiclone	US FDA	22.01.01	15518 dt. 15 August 2001
		EDQM	09.04.01	R1-CEP2001-203 Rev-01 dt. 01 March 2012
		Russia	15.02.05	IIC-000016 dt.15 March 2005
		Health Canada	02.06.08	DMF 2008-124 dt.03 July 2008
3.	Erythromycin	US FDA	09.01.07	20137 dt. 30 January 2007
		EDQM	20.08.12	CEP2012-284
		Canada	05.02.07	2007-036 dt. 23 February 2007
4.	Erythromycin Estolate	US FDA	28.03.07	20383 dt. 06 April 2007
		Health Canada	31.03.07	2007-078 dt.19 April 2007
5.	Isoniazid	USFDA	31.01.08	21322 dt.07 February 2008
		EDQM	05.04.08	R0-CEP2008-108 Rev-01 dt. 01 March 2012
		WHO	27.02.09	APIMF 086 Prequalified 07 December 2011
		UK MHRA	04.03.09	MFD-20048-1-07745-0001 dt. 11 March 2009
6.	Cetirizine diHCl	USFDA	26.02.08	21396 dt. 06 March 2008
		Health Canada	09.07.10	DMF 2010-148 dt. 28 July 2010
7.	Losartan Potassium	USFDA	27.08.08	21911dt. 10 September 2008
8.	Valproic acid	USFDA	05.09.08	21970 dt. 12 September 2008
9.	Ery Stearate	USFDA	10.09.08	22061 dt. 20 October 2008
10.	Flucytosine	USFDA	22.01.10	23503 dt. 27 February 2010
11.	Artemether	USFDA	22.06.10	23968 dt. 30 July 2010
		WHO	12.04.10	APIMF 120 Prequalified 26 March 2012
12.	Lumefantrine	USFDA	15.06.10	23966 dt. 30 July 2010
		WHO	27.05.10	APIMF 121 Prequalified 26 March 2012
13.	Hydroxyzine Hydrochloride	USFDA	23.07.10	24002 dt. 16 August 2010
		Health Canada	26.08.10	DMF 2010-213 dt. 12 October 2010
14.	Irbesartan	USFDA	30.07.10	24017 dt. 19 August 2010

*The Technical and Physical manufacturing capabilities exist with us for the above APIs and their intermediates. However these products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Calyx offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction. Products under patent offered only for exempted research, clinical and development purposes. Only non-infringing products and processes are offered, subject to patent status verification by client.

Calyx Chemicals & Pharmaceuticals Limited

Regd. Office: Unit No.110, Marwah's Complex, Krishanlal Marwah Marg, Off Saki Vihar Road, Andheri (East), Mumbai 400072, India.
Tel: 91-22-28571191, Fax: 91-22-66466416

USA Contact: 11728 E. Imperil Highway, Norwalk, CA 90650, Tel: 213-291-7773
Email: sales@calyxindia.com, crams@calyxindia.com, sales@calyxusa.com, crams@calyxusa.com, www.calyxindia.com

"Calyx Chemicals and Pharmaceuticals Limited (the "Company") is proposing to make, subject to receipt of requisite approvals, market conditions and other considerations, an Initial Public Offering of its equity shares (the "IPO") and has filed the Draft Red Herring Prospectus (the "DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of the BRLMs, i.e. PL Capital Markets Private Limited at www.plindia.com and YES Bank Limited at www.yesbank.in and is also available on the website of the Company at www.calyx-pharma.com. Potential investors should note that investment in equity shares involves a degree of risk. For details, please refer to the DRHP, including the section titled "Risk Factors" of the DRHP. This publicity material does not constitute an offer of securities in any jurisdiction, including the United States of America ("USA"). Securities may not be offered or sold in the USA without registration under the U.S. Securities Act of 1933 as amended, or an exemption therefrom. The Company has not and does not intend to offer any securities to the public in the USA.